INmune Bio (NASDAQ:INMB) Stock Price Down 2.4% – Time to Sell?

INmune Bio, Inc. (NASDAQ:INMB)’s share price traded down 2.4% on Friday . The stock traded as low as $1.24 and last traded at $1.24. 150,547 shares changed hands during trading, a decline of 53% from the average session volume of 322,965 shares. The stock had previously closed at $1.27.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Lucid Cap Mkts raised shares of INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. Wall Street Zen downgraded shares of INmune Bio from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

INmune Bio Price Performance

The company has a market capitalization of $32.96 million, a PE ratio of -0.74 and a beta of 1.03. The company’s fifty day moving average is $1.37 and its 200-day moving average is $1.48.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04.

Hedge Funds Weigh In On INmune Bio

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in INmune Bio in the fourth quarter worth $32,000. XTX Topco Ltd grew its holdings in INmune Bio by 41.3% in the fourth quarter. XTX Topco Ltd now owns 68,865 shares of the company’s stock worth $107,000 after purchasing an additional 20,121 shares during the last quarter. Quadrature Capital Ltd purchased a new position in INmune Bio in the fourth quarter worth $26,000. Jain Global LLC purchased a new position in INmune Bio in the fourth quarter worth $66,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in INmune Bio by 20.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after purchasing an additional 8,427 shares during the last quarter. 12.72% of the stock is owned by hedge funds and other institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.